A phase 1 study of the pharmacokinetics of nucleoside analog trifluridine and thymidine phosphorylase inhibitor tipiracil (components of TAS-102) vs trifluridine alone.

ABSTRACT: Background Trifluridine, a thymidine-based chemotherapeutic, has limited bioavailability after clinical administration as it is rapidly degraded via thymidine phosphorylase. An oral combination tablet combines trifluridine with a potent thymidine phosphorylase inhibitor, tipiracil hydrochloride. This study's objective was to evaluate whether trifluridine/tipiracil (TAS-102) administration increases trifluridine exposure vs trifluridine alone. Methods This open-label pharmacokinetic study randomly assigned patients with advanced solid tumors into two groups. On the morning of day 1, one group received a single 35 mg/m² dose of trifluridine/tipiracil and the other group received a single 35-mg/m² dose of trifluridine. Both groups received trifluridine/tipiracil 35 mg/m<

SUBMITTER: Cleary JM 

PROVIDER: S-EPMC5352756 | biostudies-literature | 2017 Apr

REPOSITORIES: biostudies-literature